Abstract
Macrophage migration inhibitor factor (MIF) is a highly conserved and evolutionarily ancient mediator with pleiotropic effects that has been implicated in tumor growth and progression. MIFs function is unique among cytokines and its effects extend to multiple processes fundamental to tumorigenesis such as tumor proliferation, evasion of apoptosis, angiogenesis and invasion. These pleiotropic functional aspects are paralleled by MIFs unique signaling properties, which involve activation of the ERK-1/2 and AKT pathways and the regulation of JAB1, p53, SCF ubiquitin ligases and HIF-1. These properties reflect features central to growth regulation, apoptosis and cell cycle control than is typical for an immune cytokine. The significance of these pro-tumorigenic properties has found support in several in vitro and in vivo models of cancer and in the positive association between MIF production and tumor aggressiveness and metastatic potential in a variety of human tumors.
Keywords: Macrophage migration inhibitory factor, HIF-1, P53, TAM, angiogenesis, tumor progression, CD44, CD74
Current Pharmaceutical Design
Title: Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Volume: 14 Issue: 36
Author(s): Carlo Bifulco, Katy McDaniel, Lin Leng and Richard Bucala
Affiliation:
Keywords: Macrophage migration inhibitory factor, HIF-1, P53, TAM, angiogenesis, tumor progression, CD44, CD74
Abstract: Macrophage migration inhibitor factor (MIF) is a highly conserved and evolutionarily ancient mediator with pleiotropic effects that has been implicated in tumor growth and progression. MIFs function is unique among cytokines and its effects extend to multiple processes fundamental to tumorigenesis such as tumor proliferation, evasion of apoptosis, angiogenesis and invasion. These pleiotropic functional aspects are paralleled by MIFs unique signaling properties, which involve activation of the ERK-1/2 and AKT pathways and the regulation of JAB1, p53, SCF ubiquitin ligases and HIF-1. These properties reflect features central to growth regulation, apoptosis and cell cycle control than is typical for an immune cytokine. The significance of these pro-tumorigenic properties has found support in several in vitro and in vivo models of cancer and in the positive association between MIF production and tumor aggressiveness and metastatic potential in a variety of human tumors.
Export Options
About this article
Cite this article as:
Bifulco Carlo, McDaniel Katy, Leng Lin and Bucala Richard, Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor, Current Pharmaceutical Design 2008; 14 (36) . https://dx.doi.org/10.2174/138161208786898608
DOI https://dx.doi.org/10.2174/138161208786898608 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Trends and Future Strategies for the Global Impact of COVID-19 Pandemic
Coronaviruses Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry TRP Channels as A Newly Emerging Non-Voltage-Gated Ca2+ Entry Channel Superfamily
Current Pharmaceutical Design Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Ethnopharmacological and Toxicological Properties of Bioactive Compounds from <i>Aloe barbadensis</i> (Miller), <i>Aloe vera</i>
Current Bioactive Compounds Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents
Current Medicinal Chemistry Psychiatric Side Effects of Interferon Treatment
Current Drug Safety The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Targeting Pain-evoking Transient Receptor Potential Channels for the Treatment of Pain
Current Neuropharmacology Renal Development: A Complex Process Dependent on Inductive Interaction
Current Pediatric Reviews Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design